Loading...
Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?
You are evaluating a 47-year-old man with revised international staging system stage III myeloma who recently underwent an autologous stem cell transplant after receiving 6 cycles of carfilzomib, lenalidomide, and dexamethasone for newly diagnosed disease. Fluorescence in situ hybridization testing...
Saved in:
| Published in: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913499/ https://ncbi.nlm.nih.gov/pubmed/31808853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|